Study of 9MW2821 for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have triple-negative breast cancer that has spread or cannot be removed by surgery.
- You must be healthy enough to perform daily activities (ECOG score 0 or 1).
- You must be willing to provide a tumor tissue sample.
- You cannot have serious health problems like uncontrolled diabetes, lung disease, or recent blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This trial tests a new combination treatment for people with advanced triple-negative breast cancer who have not yet received treatment for their advanced disease. It aims to see if the combination can help shrink or control the cancer.
This trial tests a new drug called JS212, given alone or with other medicines, for people with advanced triple-negative breast cancer that has not spread too much before. It aims to see if the drug can shrink tumors or slow the disease.
This study tests a new drug (9MW2821) against standard chemotherapy for people with triple-negative breast cancer that has spread or come back after prior treatments. The new drug is designed to target and destroy cancer cells more precisely, potentially offering better outcomes.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.